-
1.发明公开公开(公告)号：US20230399621A1
公开(公告)日：2023-12-14
申请号：US18331042
申请日：2023-06-07
发明人： Thomas ICHIM , Amit PATEL , Courtney BARTLETT
IPC分类号： C12N5/0775 , C12N5/00
CPC分类号： C12N5/0662 , C12N5/0018 , C12N2501/165 , C12N2501/155 , C12N2501/145 , C12N2501/125 , C12N2501/22 , C12N2501/2303 , C12N2501/2306
摘要： Disclosed are means, methods and compositions of matter useful for generation of conditioned media from mesenchymal stem cells (MSC). In one embodiment MSC are extracted, dedifferentiated into inducible pluripotent stem cells (iPSC) and said iPSC are differentiated into the MSC lineage. The differentiated MSC are utilized as producers of conditioned media for therapeutic purposes. In one embodiment MSC are subjected to one or more stressors, after which conditioned media is extracted and in some cases concentrated. Said conditioned media can be utilized as a therapeutic agent or can be used in the generation of immune modulatory cells.
-
2.发明公开公开(公告)号：US20230392113A1
公开(公告)日：2023-12-07
申请号：US18331029
申请日：2023-06-07
发明人： Thomas ICHIM , Amit PATEL , Courtney BARTLETT
IPC分类号： C12N5/0735
CPC分类号： C12N5/0606 , C12N2500/30 , C12N2506/45
摘要： Disclosed are methods, compositions of matter and protocols useful for restoring/enhancing endometrial function by administration of regenerative cells. In one embodiment cells capable of decreasing fibrosis, stimulation of angiogenesis, and augmenting hormone responsiveness are administered systemically or locally. In some embodiments cells utilized are autologous or allogeneic mesenchymal stem cells.
-
3.发明公开公开(公告)号：US20240041937A1
公开(公告)日：2024-02-08
申请号：US18366527
申请日：2023-08-07
发明人： Thomas ICHIM , Amit PATEL , Courtney BARTLETT
IPC分类号： A61K35/28 , C12N5/0775 , C12N5/078 , C12N5/0789
CPC分类号： A61K35/28 , C12N5/0662 , C12N5/0644 , C12N5/0647 , C12N5/065
摘要： Disclosed are prophylactic and therapeutic approaches to Orthopox viral infections. In one embodiment the invention teaches utilization of regenerative cell conditioned media as a prophylactic/therapeutic agent. Synergies with antivirals and immunotherapies are further described. In one specific embodiment, mesenchymal stem cells are activated in vitro with trigger agents activating Toll-Like Receptors (TLRs), NOD-Like Receptors (NLRs), and RIG-I-Like Receptors (RLRs) and conditioned media is isolated and utilized as a therapeutic. Quantification of activity is performed by assessment of antiviral activity and/or ability to stimulate NK mediated cytolysis. Additionally, means of treating Orthopox viral infections (Smallpox, Monkeypox, etc.) by direct administration of stem cells and/or products thereof such as exosomes are disclosed.
-
公开(公告)号：US20240041935A1
公开(公告)日：2024-02-08
申请号：US18363642
申请日：2023-08-01
发明人： Thomas ICHIM , Amit PATEL , Courtney BARTLETT
CPC分类号： A61K35/28 , C12N5/0665 , A61K35/16 , A61K38/1808 , A61K38/30 , A61K38/1841 , A61K38/1891 , A61K45/06
摘要： Disclosed are means of treatment for age related or premature reproductive failure through concurrent administration of regenerative cells together with adjuvants capable of enhancing activity of said regenerative cells. In one embodiment, the invention provides administration of autologous bone marrow mononuclear cells in the endometrium and ovarian tissue. Administration of said type of regenerative cells is combined with anti-oxidants and/or regenerative adjuvants capable of reducing inflammation and/or fibrosis, as well as providing a suitable environment for optimal regenerative function of stem cells.
-
公开(公告)号：US20240002792A1
公开(公告)日：2024-01-04
申请号：US18318465
申请日：2023-05-16
发明人： Thomas ICHIM , Amit PATEL , Courtney BARTLETT
IPC分类号： C12N5/078
CPC分类号： C12N5/0634 , C12N2502/1352 , C12N2501/50
摘要： The invention provides means, methods and some compositions of matter useful to treat ovarian failure. In one embodiment progenitor cells possessing ability to differentiate along the monocytic and granulocyte linages are utilized as a source of cytokines for stimulation of ovarian repair/regeneration. Generation of said cells, such as classically termed myeloid derived suppressor cells is performed from sources including cord blood, bone marrow, mobilized peripheral blood and pluripotent stem cells. The invention further provides means of suppressing fibrosis and ongoing inflammation associated with ovarian dysfunction.
-
公开(公告)号：US20240041936A1
公开(公告)日：2024-02-08
申请号：US18366516
申请日：2023-08-07
发明人： Thomas ICHIM , Amit PATEL , Courtney BARTLETT
IPC分类号： A61K35/28 , A61K35/16 , A61N5/067 , C07K16/28 , A61K31/366 , A61K31/382 , A61K31/58 , A61K31/164
CPC分类号： A61K35/28 , A61K35/16 , A61N5/067 , C07K16/2887 , A61K31/366 , A61K31/382 , A61K31/58 , A61K31/164
摘要： Disclosed are means, methods and compositions of matter for prevention of hair loss and/or regeneration of hair follicles utilizing stem cell-based approaches and synergies with stimulating and/or hormone modulating agents. In one embodiment the invention discloses specific platelet rich plasma (PRP) combinations alone or with bone marrow stem cells to augment hair restoration and stimulate expansion of hair follicle associated T regulatory cell.
-
公开(公告)号：US20230372402A1
公开(公告)日：2023-11-23
申请号：US18311625
申请日：2023-05-03
发明人： Thomas ICHIM , Amit PATEL , Courtney BARTLETT
IPC分类号： A61K35/28 , A61K38/18 , C12N5/0775
CPC分类号： A61K35/28 , A61K38/18 , C12N5/0662 , C12N2501/12 , C12N2501/115 , C12N2501/15 , C12N2501/105 , C12N2501/734
摘要： Disclosed are novel means of generating cells uniquely suited for treatment of ovarian failure. In one embodiment regenerative cells are pretreated with growth factor-comprising composition(s), wherein the growth factor(s) may be cytokines, peptides, and/or proteins. In another embodiment regenerative cells are cultured with primed plasma extracts. In another embodiment, regenerative cells are cultured under hypoxic conditions together with cytokines prior to administration to an individual. Regenerative cells useful for the current invention including mesenchymal and hematopoietic stem cells, as well as various growth factor producing cells.
-
8.发明公开公开(公告)号：US20230330193A1
公开(公告)日：2023-10-19
申请号：US18300222
申请日：2023-04-13
发明人： Thomas ICHIM , Amit PATEL , Courtney BARTLETT
CPC分类号： A61K38/446 , C12Y115/01001 , A61K33/04 , A61K38/063 , A61K33/00 , A61K31/436 , A61K35/28 , A61K45/06
摘要： Disclosed are means of augmenting efficacy of stem cell therapy for articular tissues through introduction of a step to reduce oxidative stress inside the joint before administration of stem cells. In one embodiment reduction of oxidative stress and/or inflammation is accomplished by administration of anti-oxidant agents locally in the tissue in which stem cell administration is anticipated to. In one embodiment administration of hydrogen gas is provided as a “preconditioning” step before administration of stem cell therapy. In one embodiment cell therapy is a same day non manipulated procedure involving administration of bone marrow aspirate.
-
9.发明公开公开(公告)号：US20230399626A1
公开(公告)日：2023-12-14
申请号：US18331048
申请日：2023-06-07
发明人： Thomas ICHIM , Amit PATEL , Courtney BARTLETT
IPC分类号： C12N5/071
CPC分类号： C12N5/0692 , C12N2501/60
摘要： Disclosed are means, methods and compositions of matter useful for generation of conditioned media from endothelial progenitor cells (EPC). In one embodiment, EPC are extracted, dedifferentiated into inducible pluripotent stem cells (iPSC) and said iPSC are differentiated into the EPC lineage. The differentiated EPC are utilized as producers of conditioned media for therapeutic purposes. In one embodiment EPC are subjected to one or more stressors, after which conditioned media is extracted and in some cases concentrated. Said conditioned media can be utilized as a therapeutic agent or can be used in the generation of immune modulatory cells.
-
公开(公告)号：US20230374463A1
公开(公告)日：2023-11-23
申请号：US18311768
申请日：2023-05-03
发明人： Thomas ICHIM , Amit PATEL , Courtney BARTLETT
IPC分类号： C12N5/0775
CPC分类号： C12N5/0662 , C12N2506/45 , C12N2500/02
摘要： Disclosed are compositions of matter, protocols, and procedures useful for generation of mesenchymal stem cells capable of withstanding the microenvironment of degenerating ovaries. In one embodiment mesenchymal stem cells are pre-treated under conditions capable of upregulating cytoprotective responses and genes, such as HIF-1 alpha and hemoxygenase. In other embodiments mesenchymal stem cells are temporarily pulsed with hypoxia and/or acidity in order to prime them for the harsh environment of degenerating ovarian tissue. Through this approach increased viability of mesenchymal stem cell subsequent to intra-ovarian administration is achieved.
-
-
-
-
-
-
-
-
-
搜索结果
30 条记录 (耗时 0.017 秒)
